# Junta clínica — PT-pseudo_87cbc2052e90 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_87cbc2052e90",
  "pid": "PT-pseudo_87cbc2052e90",
  "task": 1,
  "psa": 8.8,
  "age": 70,
  "months": 1,
  "pirads": "3",
  "psad": 0.267,
  "psav": 0.96,
  "psap": 8.5,
  "vol": 33.02,
  "dre": "Normal",
  "bx": "None",
  "cspca": 0.7255827,
  "medhx": "Hypertension, Chronic kidney disease, Benign prostatic hyperplasia",
  "meds": "amlodipine, valsartan, lisinopril, metoprolol, tamsulosin",
  "notes": "PSA 8.8 ng/mL. PI-RADS 3. PSAD 0.27. Prostate volume 33 mL. csPCa 0.73.",
  "pmhx": [
    "Hypertension",
    "Chronic kidney disease",
    "Benign prostatic hyperplasia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "69 kg",
    "height": "166 cm",
    "bmi": "25.0",
    "bp": "141/71 mmHg",
    "hr": "64 bpm",
    "smoking": "Ex-smoker (36 pack-yr, quit 2020)",
    "last_dental": "3 yr ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "22 Jan 2025",
  "enc_ref": "Dr. K. Bakker (GP)",
  "enc_type": "Follow-up - PSA + MRI",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Urgent evaluation sought after a marked elevation in prostate-specific antigen to 8.8 ng/mL accompanied by recent multiparametric MRI results."
    },
    {
      "s": "History",
      "t": "At seventy years of age, this retired warehouse worker originally sought urological care three years ago for urinary complaints, though current attendance focuses entirely on monitoring a rising prostate-specific antigen trajectory. His medical background encompasses hypertension, chronic kidney disease, and benign prostatic hyperplasia, currently addressed with amlodipine, valsartan, lisinopril, metoprolol, and tamsulosin. Lower urinary tract distress remains minimal, yielding an International Prostate Symptom Score of 2 out of 35, while he explicitly denies hematuria or erectile dysfunction. He shares a ground-floor apartment with his wife, navigates daily tasks using seated exercise programs due to restricted mobility, and ingests roughly five alcoholic beverages each week. A former smoker with a 36 pack-year accumulation, he ceased tobacco use in 2020. Preventive health maintenance includes routine dental visits and recent ophthalmologic evaluation for cataract tracking. Surgical history features a laparoscopic cholecystectomy completed twenty years ago and a minor arthroscopic knee procedure in 2018, both healed without complications. He reports zero instances of bone pain, unexplained weight reduction, or systemic illness, maintaining steady general health."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: uniformly smooth; size and consistency: within normal limits; asymmetry or nodularity: absent. General assessment shows no abnormalities, recording a blood pressure of 141/71 mmHg and a steady cardiac rhythm at 64 beats per minute. Peripheral tissues lack edema, and no lymph node enlargement is detected. Abdominal palpation identifies a relaxed, non-tender cavity without distension."
    }
  ],
  "occupation": "retired warehouse worker",
  "marital": "Married",
  "living": "Lives in ground-floor apartment with partner",
  "next_of_kin": "Sibling (sister)",
  "recent_other": [
    "Dental — biannual check-up",
    "Ophthalmology — cataract review"
  ],
  "alcohol": "5 units / week",
  "exercise": "Limited mobility — chair-based exercises only",
  "ipss": "IPSS score: 2/35 (mild LUTS)",
  "admin": "Patient self-employed; flexible appointment slots requested.",
  "mri_hospital": "OLVG (Amsterdam)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_87cbc2052e90
Task: 1

Encounter: Urology - outpatient on 22 Jan 2025.
Referrer: Dr. K. Bakker (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 70-year-old male
  - PSA: 8.8 ng/mL
  - mpMRI — PI-RADS score: 3 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.267 ng/mL²
  - PSA velocity: 0.96 ng/mL/yr
  - Prior PSA: 8.5 ng/mL
  - Prostate volume: 33.02 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7255827 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Chronic kidney disease, Benign prostatic hyperplasia
  - Problem list / PMHx: Hypertension, Chronic kidney disease, Benign prostatic hyperplasia
  - Current medication: amlodipine, valsartan, lisinopril, metoprolol, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 8.8 ng/mL. PI-RADS 3. PSAD 0.27. Prostate volume 33 mL. csPCa 0.73.

Vitals: weight 69 kg, height 166 cm, BMI 25.0, BP 141/71 mmHg, HR 64 bpm. Smoking: Ex-smoker (36 pack-yr, quit 2020).

Chief complaint: Urgent evaluation sought after a marked elevation in prostate-specific antigen to 8.8 ng/mL accompanied by recent multiparametric MRI results.

History: At seventy years of age, this retired warehouse worker originally sought urological care three years ago for urinary complaints, though current attendance focuses entirely on monitoring a rising prostate-specific antigen trajectory. His medical background encompasses hypertension, chronic kidney disease, and benign prostatic hyperplasia, currently addressed with amlodipine, valsartan, lisinopril, metoprolol, and tamsulosin. Lower urinary tract distress remains minimal, yielding an International Prostate Symptom Score of 2 out of 35, while he explicitly denies hematuria or erectile dysfunction. He shares a ground-floor apartment with his wife, navigates daily tasks using seated exercise programs due to restricted mobility, and ingests roughly five alcoholic beverages each week. A former smoker with a 36 pack-year accumulation, he ceased tobacco use in 2020. Preventive health maintenance includes routine dental visits and recent ophthalmologic evaluation for cataract tracking. Surgical history features a laparoscopic cholecystectomy completed twenty years ago and a minor arthroscopic knee procedure in 2018, both healed without complications. He reports zero instances of bone pain, unexplained weight reduction, or systemic illness, maintaining steady general health.

Physical examination: DRE — texture: uniformly smooth; size and consistency: within normal limits; asymmetry or nodularity: absent. General assessment shows no abnormalities, recording a blood pressure of 141/71 mmHg and a steady cardiac rhythm at 64 beats per minute. Peripheral tissues lack edema, and no lymph node enlargement is detected. Abdominal palpation identifies a relaxed, non-tender cavity without distension.

Patient info: retired warehouse worker; Married; Lives in ground-floor apartment with partner.
Next of kin: Sibling (sister).

Lifestyle: alcohol 5 units / week; exercise Limited mobility — chair-based exercises only; IPSS score: 2/35 (mild LUTS).

Recent other appointments: Dental — biannual check-up; Ophthalmology — cataract review.
Admin: Patient self-employed; flexible appointment slots requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.56
  uncertainty  +/- 0.13 epistemic (95% band 0.30-0.81); among patients I cannot tell apart the outcome was 0.99 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: never biopsied. My criterion answers BIOPSY.

The criterion: sample when the mpMRI shows a PI-RADS 3 or higher lesion; defer at PI-RADS 1-2. In the labelled series this criterion matched the reading urologist in 24 of 24 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 24 labelled men in this same situation (None prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.91: PI-RADS 4, PSA 9.3, PSAD 0.296, age 66, DRE Normal -> BIOPSY (clear). He wrote: "P4 in 66 year old patient."
  2. distance 2.31: PI-RADS 4, PSA 13.9, PSAD 0.177, age 65, DRE Normal -> BIOPSY (clear). He wrote: "P4 in 65 year old patient"
  3. distance 2.43: PI-RADS 2, PSA 5.0, PSAD 0.1, age 77, DRE Normal -> DEFER (clear). He wrote: "older patient with non-elevated, stable PSA. some comorbidity limits expected survival. MRI without significant lesions. Low risk of higher risk prostate cancer -> no bi…"

PRECEDENT: BIOPSY (weighted vote 0.70 for biopsy). Distance-weighted precedent is strong here (0.92 leave-one-out).

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 24 labelled traces in this situation (None prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines state that MRI-directed US-guided prostate biopsy is the standard of care. "MRI-directed US-guided prostate biopsy is now the standard of care, although MRI in-bore biopsy is offered in a few centres." This suggests that the PI-RADS score is a key factor in the decision.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, I disagree with the suggestion of biopsy because the guideline suggests that for PI-RADS 3 lesions, the decision depends on clinical suspicion, which is not fully established here. EXPERT-COHORT, your criterion matching 24/24 cases where PI-RADS $\ge 3$ leads to biopsy, does not account for the PSA density threshold mentioned in the guideline for omitting biopsy when clinical suspicion is low.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the prior biopsy status: None means the indication stands, but the guideline suggests risk stratification based on other factors.
radiology_report - whether the lesion is compared against an earlier study: Unchanged does not support re-sampling, new or larger does.
psa_trend - the PSA velocity: 0.96 ng/mL/yr, which is a factor in risk stratification mentioned in the guideline.
laboratory_results - the PSA density: 0.267 ng/mL², which is a factor in risk stratification mentioned in the guideline.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on whether the PI-RADS 3 finding, combined with the PSA velocity and PSA density, meets the threshold for MRI-directed biopsy according to the EAU guidelines.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine whether the lesion is compared against an earlier study.
  psa_trend (get_psa_trend) -> Determine the risk stratification factor based on the PSA velocity.
  previous_notes (get_previous_notes) -> Determine the indication based on the prior biopsy status.
  laboratory_results (get_lab_results) -> Determine the risk stratification factor based on the PSA density.

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What does the radiology_report state regarding whether the lesion is compared against an earlier study?
  Q2. What does the psa_trend indicate regarding the risk stratification mentioned in the EAU guidelines?
  Q3. What does the laboratory_results indicate regarding the PSA density threshold for omitting biopsy?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
LESION: size and zone of the index lesion, as the report words it: "a discrete region of intermediate signal intensity within the right posterior peripheral zone at the mid-gland, spanning roughly 8 by 6 mm."

psa_trend
The risk stratification factor based on the PSA velocity: The trend shows a rise from 1.3 ng/mL (Dec 2023) to 8.8 ng/mL (Jan 2025), indicating a significant upward trajectory.

previous_notes
The indication based on the prior biopsy status: Prior biopsy: None.

laboratory_results
The risk stratification factor based on the PSA density: The PSA density is 0.267 ng/mL², which is a factor in risk stratification mentioned in the EAU guidelines.

WHAT I DID NOT OPEN
family-history anamnesis, because the clinical decision hinges on the imaging and trend data first.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 3 lesion located in the right posterior peripheral zone at mid-gland, spanning roughly 8 by 6 mm. (from radiology_report)
PSA velocity shows a significant upward trajectory from 1.3 ng/mL (Dec 2023) to 8.8 ng/mL (Jan 2025). (from psa_trend)

AGAINST sampling this patient now
PSA density of 0.267 ng/mL² is a factor in risk stratification mentioned in the EAU guidelines. (from laboratory_results)

WHERE THIS LEANS
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 8.80 ng/mL over 5 points spanning 13 months; velocity +6.78 ng/mL per year; doubling time about 5 months.
PROJECTION at 6 months: 13.2 ng/mL, conformal 95% band 3.8-45.9.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.57
  uncertainty  +/- 0.12 epistemic (95% band 0.33-0.81), of which 0.00 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 61% of the time over the 31 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.56  ('discuss' tier; weight 1.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.57  ('discuss' tier, fusion_full; weight 1.5)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=0.70  (k=3 precedents; does not vote)
  EXPERT-COHORT      BIOPSY  (rule pirads_ge_3; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: cohort criterion (pirads_ge_3) — carried by EXPERT-COHORT.
PANEL ANSWER: BIOPSY. It matched the reading urologist in 24 of 24 labelled cases in exactly this situation (never biopsied).

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents retrieved by the registrar appear to have answered all the moderator's questions. The `radiology_report` addressed Q1, `psa_trend` addressed Q2, and `laboratory_results` addressed Q3.

ALIGNMENT WITH THE PANEL
The retrieved findings support the PANEL-PROTOCOL's answer of BIOPSY. Specifically, the `radiology_report` identified a lesion, the `psa_trend` showed a significant upward trajectory, and the `laboratory_results` provided the PSA density value, all of which were weighed by the experts.

THE OPEN QUESTIONS, ONE BY ONE
Q1. The `radiology_report` states the comparison is "new."
Q2. The `psa_trend` indicates a significant upward trajectory from 1.3 ng/mL (Dec 2023) to 8.8 ng/mL (Jan 2025).
Q3. The `laboratory_results` indicate the PSA density is 0.267 ng/mL².

WHAT CARRIES WEIGHT, AND WHY
The PI-RADS 3 finding from the MRI, the significant upward PSA velocity, and the PSA density value are the most relevant variables. These factors directly relate to the EAU guideline's focus on MRI-directed biopsy and risk stratification.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a biopsy, as the evidence retrieved—a PI-RADS 3 lesion, a rising PSA trend, and the specific PSA density—aligns with the panel's conclusion and the EAU guideline's emphasis on MRI-directed biopsy for these findings.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

70y male, PSA 8.8, PSAD 0.267, biopsy-naive, PI-RADS 3. Biopsy is indicated due to PI-RADS 3 and elevated PSA density, which supports sampling. No prior pathology to reconcile findings. Alternative plan is MRI-directed US-guided biopsy.

What carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes, laboratory_results
